risks of glp 1 agonists Mapping the effectiveness and GLP-1 receptor - Nature Medicine GLP-1 receptor agonists in pediatric

doi:10.1001/jamainternmed.2019.1859

For people who prefer oral options, research-backed supplements like Motus (oral) by Tonum have reported strong human clinical resultsabout 10.4 percent average weight loss over six months in trials

Lipo-C formulations are compounded products that haven't been individually reviewed by the FDA, and they're not FDA-approved for weight loss or any specific medical indication

States which previously had coverage such as California, New Hampshire, Pennsylvania and South Carolina have also eliminated GLP-1 coverage for weight loss in recent months

Important considerations include potential drug interactions and the risk of masking serious complications

All participants were currently using a GLP-1RA, with semaglutide and tirzepatide being the most common